Biotech giant Incannex Healthcare Ltd (NASDAQ: IXHL) shared a business presentation of its newly formed psychedelic-assisted therapies subsidiary company, Psychennex Pty Ltd.
Psychennex will take advantage of Australia’s new psychedelics regulations through clinical research programs and service delivery, including MDMA-assisted psychotherapy for PTSD, psilocybin-assisted psychotherapy for TRD and psilocybin-assisted psychotherapy for GAD once approved.
The new business will gather all of Incannex’s psychedelic-related assets, including IP from PsiGAD clinical trials and licensing of future psychedelic trials; product development (see the company’s agreement with Catalent on cGMP psilocybin, plus virtual reality-augmented psychedelic-assisted psychotherapy😉 distribution contracts for …